Gastroparesis after Lung Transplantation: A Single-Center Experience
1St. Joseph's Hospital and Medical Center, Phoenix, AZ
2University of Arizona College of Medicine, Phoenix, AZ
3Grand Canyon University, Phoenix, AZ
4St. Joseph's Hospital and Medical Center, Phoenix, AZ
5University of Arizona College of Public Health, Phoenix, AZ
6Arizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ
7Norton Thoracic Institue, St. Joseph's Hospital and Medical Center, Phoenix, AZ.
Meeting: 2018 American Transplant Congress
Abstract number: C259
Keywords: Lung transplantation
Session Information
Session Name: Poster Session C: Lung: All Topics
Session Type: Poster Session
Date: Monday, June 4, 2018
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall 4EF
Objective: Gastroparesis (GP), common in patients undergoing lung transplantation (LTx) for end-stage lung disease, can affect quality of life and absorbency of immunosuppressants. In this study, we examined incidence and risk factors for GP post-LTx and assessed the safety and efficacy of botulinum toxin-A (BTX) for treatment of GP post-LTx.
Methods: We reviewed charts of patients who underwent LTx at our center from 01/1/2013–12/22/2015. The incidence of GP was evaluated by pre-LTx gastric scintigraphy (GES) and again 1-year post-LTx. Logistic regression methods were used to ascertain variables associated with GP at 1-year post-LTx. Efficacy of intervention for GP was assessed by symptom relief and by 2-hour retention on GES 1 year post-LTx.
Results: In total, 232 LTx patients with GES data were included. 56 patients (24.1%) had evidence of GP on GES post-LTx; only 8 of these patients (14.3%) had pre-LTx GP. 30/55 (54.5%) patients with symptomatic GP received treatment with pyloric BTX injection (n=5), balloon dilation (n=5), or both (n=20). A higher proportion of patients with post-LTx GP were patients undergoing lung retransplantation than those undergoing first-time LTx (p <0.001). Gastroesophageal reflux disease (GERD) treated medically (48.2%) or surgically (19.7%) was more common in patients with GP than in patients without (p=0.034). Of the 25 patients who received pyloric BTX injection at a mean of 196.3±153 days post-LTx, 19 (76.0%) were asymptomatic 1 year post-LTx. Mean 2-hour retention rates were 26±22.9% in treated patients compared to 50±22.2% in untreated patients with GP.
Conclusion: This large, single-center study with objective GES data shows the high incidence of post-transplant GP. GP was associated with retransplantation and GERD. Pyloric BTX injection may may ameliorate symptoms of GP post-LTx. Treatment algorithms for symptomatic GP in LTx patients must be better defined by multicenter prospective studies.
CITATION INFORMATION: Biswas Roy S., Davis M., Rodriguez F., Serrone R., Kang P., Ipsen T., Smith M., Bremner R., Huang J., Huang J. Gastroparesis after Lung Transplantation: A Single-Center Experience Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:
Roy SBiswas, Davis M, Rodriguez F, Serrone R, Kang P, Ipsen T, Smith M, Bremner R, Huang J, Huang J. Gastroparesis after Lung Transplantation: A Single-Center Experience [abstract]. https://atcmeetingabstracts.com/abstract/gastroparesis-after-lung-transplantation-a-single-center-experience/. Accessed May 16, 2025.« Back to 2018 American Transplant Congress